|---|---|
|Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-12/23i biologic and MTX combination therapy if the patient has severe psoriasis.|Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-12/23i biologic and MTX combination therapy if the patient has severe psoriasis.|
|14. Switch to a different TNFi biologic + MTX over switching to a different TNFi biologic monotherapy (PICO 33)|Very low|